Investor Overview


About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.


Recent News

Natera Announces Pricing of Follow-On Offering  -  10/16/2019
SAN CARLOS, Calif. , Oct. 16, 2019 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,714,286 shares of its common stock at a price to the public of $35.00 per share. More »
Natera Launches Proposed Follow-On Offering  -  10/15/2019
SAN CARLOS, Calif. , Oct. 15, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $175,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day More »
Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business  -  10/3/2019
  SAN CARLOS, Calif. , Oct. 3, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA ), a global leader in cell-free DNA testing, today announced it will review recent progress in its oncology business, including the positive draft local coverage decision for Signatera ™ in colorectal cancer and More »
Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring  -  9/25/2019
  CAMBRIDGE, Mass. and SAN CARLOS, Calif. , Sept. 25, 2019 /PRNewswire/ -- Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA) today announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical More »
CBR to Acquire Natera's Evercord™ Cord Blood Business  -  9/13/2019
Sharpens Natera's Focus on Reproductive Health, Oncology and Organ Transplant SAN CARLOS, Calif. , Sept. 13, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) and   CBR (Cord Blood Registry )  today announced the acquisition by CBR, a California Cryobank Life Sciences company, and the world's More »

Upcoming Events

More events are coming soon.

Past events

Thursday, 10/10/19 at 1:30 PM PDT

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.